#5-26E. Skeletal Paradox: Do GLP-1 Receptor Agonists Protect or Imperil Bone Health? (JAMA Netw Open, 2026)

Does the rapid weight loss induced by GLP-1 receptor agonists compromise bone integrity and increase fracture risk? In this target trial emulation involving over 130,000 adults with type 2 diabetes, investigators compared GLP-1 receptor agonists with DPP-4 inhibitors to evaluate three-year fragility fracture risks. Remarkably, GLP-1 receptor agonist initiation was associated with a significant 21% lower risk of fragility fractures, particularly vertebral and hip fractures, independent of changes in weight or glycemic control. However, when critically appraising this study, clinicians must note that this is an observational study prone to residual confounding—such as unmeasured baseline bone mineral density or physical activity—and that fracture risk actually increased by 13% among users without diabetes. Ultimately, these findings challenge the traditional belief that GLP-1 receptor agonists have a net neutral effect on bone. For practicing physicians, this study offers critical evidence that can guide personalized therapeutic selection, suggesting that GLP-1 receptor agonists may serve as a bone-favorable option for diabetic patients at high risk of osteoporotic fractures.

Citation: Christopher D. Hamad, et al. Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes. JAMA Network Open. 2026. DOI: 10.1001/jamanetworkopen.2026.25141

URL: https://doi.org/10.1001/jamanetworkopen.2026.25141

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.